MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Endometrial and Cervical Cancer Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,989 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,989 works in the cohort · of 4,299,418page 30 of 40

Labels cover 4 of 1,989 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,989 of 1,989 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Ingrid Boere, Bhavana Pothuri, Olena Sukhina, Tashanna Myers, Valentina Tuninetti, Angeles Alvarez Secord +14 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affaboutunlabeled
Reply to Sentinel Lymph Node in Vulvar Cancer
Jan Hauspy, Allan Covens, Marlo Beiner, Ian Harley, Lisa Erlich, Golnar Rasty
2008· article· en· Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
#142 An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC)
Marie Plante, Janice S. Kwon, Sarah E. Ferguson, Vanessa Samouëlian, Gwénaël Ferron, Amandine Maulard +14 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Sentinel Nodes in Vulvar Cancer
Nienke C. te Grootenhuis, A.G.J. van der Zee, Helena C. van Doorn, Jacobus van der Velden, Ignace Vergote, Vanna Zanagnolo +12 more
2016· article· en· Obstetrical & Gynecological Survey· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
afffundno abstractunlabeled
Reply to C.M. Booth et al
Pamela J. Goodwin, Karla V. Ballman, Eric J. Small, M. Levine, Stephen A. Cannistra
2013· letter· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Is modified radical hysterectomy the answer?
Marie Plante, Nadeem R. Abu-Rustum
2025· editorial· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
IMAGE-Guided Brachytherapy for Primary Vaginal Cancers
William Foster, Marie‐Anne Froment, Marie‐Claude Lavallée, Éric Vigneault, S. Aubin, Damien Carignan +1 more
2019· article· en· International Journal of Radiation Oncology*Biology*Physics· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
285 Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer
Sandro Pignata, Vladyslav Sukhin, Nicoletta Colombo, Jacob Korach, Takashi Matsumoto, Susan Lalondrelle +14 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Carolyn Mccourt, Graziana Ronzino, Mark S. Shahin, Rebecca Kristeleit, Lyndsay Willmott, Oleksandr Zub +14 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
afffundunlabeled
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N. Eskander, Jung‐Yun Lee, Mansoor Raza Mirza, Domenica Lorusso, Helen Mackay, Isabelle Ray‐Coquard +11 more
2025· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About